LS081

LS081 is a small molecule iron facilitator being investigated as a novel anti-cancer agent. Unlike traditional iron chelators that deplete cancer cells of iron, LS081 employs a contrarian approach by facilitating cellular iron entry. This increase in intracellular iron levels stimulates the generation of reactive oxygen species (ROS) via Fenton chemistry, leading to oxidative damage and cell death in cancer cells. Additionally, the elevated intracellular iron enhances the activity of oxygen-dependent prolyl hydroxylases (PHDs), which require ferrous iron as a cofactor. This results in the prolyl-hydroxylation and subsequent proteasomal degradation of hypoxia-inducible factors 1-alpha (HIF-1α) and 2-alpha (HIF-2α), which are key drivers of tumor progression, angiogenesis, and cell survival under hypoxic conditions. Preclinical studies have demonstrated that LS081 inhibits the proliferation of various cancer cell lines, including prostate cancer, breast cancer, and hepatocellular carcinoma, both in vitro and in vivo, without causing significant systemic toxicity.